2024-12-11 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Review

This report analyzes Eli Lilly and Co. (LLY), a leading pharmaceutical company, based on the provided data.

**1. Performance vs. S&P 500 (VOO):**

Eli Lilly's cumulative return (583.78%) significantly outperforms the S&P 500's cumulative return (120.40%). The difference is 463.4 percentage points.  The relative divergence of 74.0% indicates LLY's performance is considerably higher than the S&P 500's over the period considered,  placing it in the upper percentile of historical performance relative to the index.  The CAGR (Compound Annual Growth Rate) from the provided table consistently showcases strong growth over various periods.

**2. Recent Price Movement:**

* **Closing Price:** 799.58
* **5-Day Moving Average:** 817.07
* **20-Day Moving Average:** 784.68
* **60-Day Moving Average:** 851.46

The stock price is currently below its 5-day and 60-day moving averages, suggesting a potential short-term downward trend, although above its 20-day moving average. The last market price of 800.64 is only slightly higher than the closing price, indicating no significant recent price jump or drop.


**3. Technical Indicators & Expected Return:**

* **RSI (73.99):**  Indicates the stock is in overbought territory, suggesting a potential pullback.
* **PPO (0.99):** Positive PPO suggests upward momentum.
* **Delta_Previous_Relative_Divergence (-1.8):** Shows a recent decrease in relative strength.
* **Expected Return (542.5%):** This exceptionally high expected return relative to the S&P 500 over the long term (2+ years) needs careful consideration, as it likely reflects past performance and doesn't guarantee future returns.  This needs further investigation and likely comes with significant risk.

**4. Recent Earnings Analysis:**

The provided earnings data shows significant volatility in EPS and revenue.  While revenue generally shows growth, EPS fluctuates significantly, including a negative EPS in 2023-11-02 and 2024-10-30.  A detailed analysis requires comparing these figures to analyst expectations (not provided).  Notably,  there's a substantial difference between Q2 2024 and Q3 2024 EPS (3.29 vs 1.08).  Further investigation is needed to understand the reasons behind these fluctuations. Revenue growth is generally positive, except for a slight dip in Q1 2024.

**5. Financial Information Analysis:**

* **Revenue:** Shows relatively consistent revenue, with a peak in Q3 2024.
* **Profit Margin:** Remains consistently high (around 80%), indicating strong profitability.
* **Equity:**  Shows an upward trend, except for a decrease between Q3 and Q4 2023.
* **ROE (Return on Equity):** Highly volatile, ranging from -0.51% to 21.88%, highlighting significant fluctuations in profitability.


**6. News and Recent Issues:**

This section requires information about recent earnings news (within the past 2 days), market outlook, and analyst opinions â€“ data not provided.


**7. Overall Analysis:**

Eli Lilly (LLY) exhibits exceptionally strong historical performance relative to the S&P 500,  indicated by high cumulative returns and a large positive alpha.  However, recent price action shows a possible short-term downturn, suggested by the moving averages and a high RSI.  Earnings data shows mixed results, with strong revenue but significant volatility in EPS, requiring further investigation to understand the underlying drivers.  The exceptionally high projected long-term return should be viewed cautiously, as it's based on past performance and doesn't guarantee future results.  Further analysis is necessary, including access to analyst expectations and recent news, to form a complete investment opinion.  The high volatility in ROE and the recent overbought RSI suggest that LLY may be susceptible to significant price fluctuations.

**8. Disclaimer:** This analysis is based solely on the provided data and does not constitute financial advice.  Independent research and consultation with a financial advisor are recommended before making any investment decisions.
